Drugs Made In America Acquisition LLC

2 deals · 0 closed · 0 liquidated · 2 in flight

Drugs Made In America Acquisition LLC is a SPAC sponsor that entered the blank-check market in 2025 with a focus on the pharmaceutical and domestic drug manufacturing sector, reflecting a broader industry interest in onshoring U.S. drug production. The firm has sponsored two special purpose acquisition companies since its debut, and as of the latest available filings, neither vehicle has completed a business combination nor been liquidated, placing both deals in active status. The sponsor's strategy centers on identifying acquisition targets within the domestic pharmaceuticals and life sciences supply chain. Visit SpacDesk and create a free account to access complete filing histories, deal timelines, and sponsor profiles for Drugs Made In America Acquisition LLC and thousands of other SPAC vehicles.

Hot Seat Score

—Insufficient history

Close rate

—

Median speed

—

Blended redemption

—

Total votes / extensions

1 / 1

Composite score combining historical close rate, median speed to deal close, and blended redemption discipline across all SPACs this sponsor has run. Higher score = institutional reputation worth retaining. Updates as new vote / closing data lands.

Win Rate (settled)

—

Total IPO Capital

$704.0M

Avg Extensions / Deal

0.0

Canonical

drugs made in america acquisition

Promote Economics (2 SPACs with data)

Avg Promote %

20.0%

Total At-Risk

$4.0M

SPACs sponsored

Symbol	Issuer	IPO	IPO Size	Status	Target	Outcome	Extensions
DMAAR	Drugs Made In America Acquisition Corp.	2025-01-29	$204.0M	Combo Announced	Power Analytics Global Corp	announced 2026-04-29	0
DMIIU	Drugs Made In America Acquisition II Corp.	2025-09-25	$500.0M	Searching	—	—	0